Don’t Give Up on Statins

It is well established that statins are considered the first-line pharmacologic therapy for dyslipidemia. Statins have been proven to reduce atherosclerotic cardiovascular disease risk; however, nearly a third of patients started on statins report muscle aches or weakness. This all too often leads to giving up on the statin, which could potentially be a life-saving medication.

Cost may be a big factor for some patients. With the 2013 ACC cholesterol therapy guidelines, you may be surprised which statin provides “bang for the buck” considering 340B prices. It just may change what you prescribe.

Instead of discontinuing statins therapy, here are some alternatives you can try and a summary of statin 340B prices:



340B Price Guide Update: Post-Exposure Prophylaxis of HIV for Adults and Adolescents

In December 2014, The World Health Organization (WHO) published a new supplemental guideline for post-exposure prophylaxis (PEP) for persons who may have been exposed to HIV. This new guideline has erased the distinction between occupational and non-occupational settings where a person may have been exposed to HIV, and has instead focused on preferred treatment regimens that apply to all possible exposed persons so as to simplify care for all patients put at risk for HIV.


Pharyngitis: To treat or not to treat? 340B Price Guide Review

When patients present with a severe sore throat and fever, it is hard not to automatically prescribe antibiotics. We want our patients to get better quickly, and the complications of untreated strep throat such as rheumatic fever and glomerulonephritis can be concerning. However, only 5-15% of adult cases of pharyngitis are caused by Group A β-hemolytic Streptococcus (GABHS).1 Most cases are actually caused by viruses such as influenza or the common cold. Identifying patients that would most benefit from antibiotic therapy can prevent unnecessary side effects of these medications and antibiotic resistance.


The 340B Drug Pricing Program is managed by the Health Resources and Services Administration (HRSA) Office of Pharmacy Affairs (OPA). For more information visit: This material is provided for general informational purposes of 340B Drug Prices only and is not an endorsement of any prescription product referenced herein. For information as to the clinical use or efficacy of a referenced product, please contact the manufacturer. 340B Price Guide makes no representations and provides no warranties as to the effectiveness or suitability for use of any prescription product referenced herein. Any referenced cost is provided as an estimate only and the actual cost is subject to change at any time and without notice. 340B Price Guide does not guarantee that the cost represented herein will be the actual and pharmacy shall at all times collect amounts due as indicated at the time of adjudication and shall be reimbursed per the terms of its agreement.'